A recent study in the Journal of Managed Care & Specialty Pharmacy reveals that 88% of patients with relapsed or refractory mantle cell lymphoma (MCL) responded to brexucabtagene autoleucel (brexu-cel) in routine practice, a figure closely mirroring the 93% response rate observed in the key ZUMA-2 trial of this CAR T-cell therapy. This real-world effectiveness shows brexu-cel’s consistency across clinical and non-clinical settings.
The ZUMA-2 trial, which enrolled 60 patients, demonstrated a 67% complete response rate, with 15% experiencing grade 3 or higher cytokine release syndrome (CRS) and 31% facing neurologic events. Brexu-cel, a CD19-directed CAR T-cell therapy, is approved for adults with relapsed or refractory MCL and B-cell acute lymphoblastic leukemia (B-ALL), addressing critical unmet needs in these populations.
Brexu-cel’s Real-World Effectiveness
The systematic review pooled data from 31 real-world cohorts, primarily from the US (20 cohorts) and Europe (10 cohorts), with one international cohort. These cohorts included patients with prior exposure to BTK inhibitors, ranging from 76.2% to 95.0%, reflecting the therapy’s use in a heavily pretreated population. The median follow-up period varied widely, from 4.2 to 25.6 months, highlighting the diversity in real-world data collection.
In MCL, the pooled overall response rate was 88% (95% CI, 85%-91%), with a complete response rate of 76% (95% CI, 68%-82%). Median overall survival (OS) was 40.3 months (95% CI, 36.2-45.8), and median progression-free survival (PFS) was 18.3 months. These outcomes compare favorably with the ZUMA-2 trial, which reported a median OS of 46.6 months and median PFS of 25.8 months, despite the real-world population’s more advanced disease stage.
Safety Profile and Adverse Events
For B-ALL, the pooled complete response rate was 74%, with a median OS of 23.3 months. Adverse events, primarily CRS and immune effector cell-associated neurotoxicity syndrome (ICANS), occurred in 12% and 20% of MCL patients, respectively. These rates were lower than those in the ZUMA-2 trial, where 15% experienced CRS and 31% faced neurologic events. The authors attributed this difference to the increased and earlier use of tocilizumab (77% of patients) and corticosteroids (61% of patients) in real-world settings, which may have mitigated severe events.
Cost and Quality-of-Life Data Gaps
The study identified significant gaps in real-world evidence on healthcare resource use, costs, and health-related quality of life (HRQOL). Median hospital stays ranged from 15 to 22 days, and 11% to 34% of MCL patients required intensive care admission. The only cost study analyzed Medicare fee-for-service and commercial registry data, finding that post-CAR T-cell therapy medical costs averaged $2,365 per patient per month, compared to $3,479 and $4,410 during first- and second-line therapies before CAR T-cell therapy. No real-world cost data were available for B-ALL, and no HRQOL studies were identified for either disease, leaving a critical gap in understanding patient-centered outcomes.
